<DOC>
	<DOCNO>NCT01513967</DOCNO>
	<brief_summary>This dual-centre , Phase I/IIa study , healthy subject subject AD investigate safety , tolerability , cognitive , behavioural effect RPh201 . The study divide three part : A , B , C</brief_summary>
	<brief_title>A Randomized SAD MAD Study Evaluating Safety Tolerability RPh201 Healthy Subjects Adults With Alzheimer 's Disease</brief_title>
	<detailed_description>The primary objective study evaluate safety tolerability RPh201 single multiple rise dos . This study design sufficient time dose escalation allow interim analysis safety tolerability data consider safe approach ass effect compound undefined mechanism therapeutic target . This protocol write flexibility accommodate inherent dynamic nature Phase I clinical study . Modifications dose , dose regimen , and/or clinical laboratory procedure currently outline may require achieve scientific goal study objective and/or ensure appropriate safety monitoring study subject . Interim safety analysis guide dose escalation/reduction trial .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>For PART A AND PART B ( healthy volunteer , SAD MAD ) healthy male female subject 18 65 year age , inclusive body mass index ( BMI ) within range 18.0 33.0 kg/m2 , inclusive , minimum weight least 50.0 kg Screening female subject childbearing potential must practice abstinence use willing continue use two medically acceptable form birth control least 1 month prior Screening ( least 3 month oral transdermal contraceptive ) least 1 month last study drug administration . Medically acceptable form contraception include oral patch hormonal contraceptive , intrauterine device , progestin implant injection , bilateral tubal ligation , doublebarrier ( i.e. , male condom addition diaphragm contraceptive sponge ) . female subject nonchildbearing potential must amenorrheic least 2 year hysterectomy and/or bilateral oophorectomy/salpingooophorectomy ( determine subject medical history ) male subject reproductive potential partner ( ) childbearing potential , must use willing continue use two medically acceptable contraceptive precaution Screening least 1 month last study drug administration . Medically acceptable form contraception include abstinence , vasectomy , male condom subject female subject must negative pregnancy test able speak , read , understand English sufficiently understand nature study , provide write informed consent , allow completion study assessment must understand provide write informed consent prior initiation protocolspecific procedure must willing able abide study requirement restriction current drug alcohol dependence ( exclude caffeine ) , base selfreport , include subject drug rehabilitation program current smoker history use tobacco product within 3 month prior Screening clinically significant abnormality physical examination , medical history , 12lead ECG ( i.e. , QTc &gt; 440 male subject &gt; 450 female subject ) , vital sign , laboratory value , judge investigator designee history presence clinically significant illness ( e.g. , cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic , musculoskeletal , psychiatric ) condition , opinion investigator would jeopardize safety subject validity study result use nonprescription drug within 7 day prior first drug administration . Subjects take overthecounter medication may still enter study , opinion investigator designee , medication receive interfere study procedure data integrity compromise safety subject use prescription medication , recreational drug , natural health product ( except vitamin mineral supplement , acceptable form birth control , hormone replacement ) within 14 day prior first drug administration throughout study , unless opinion investigator designee , product interfere study procedure data integrity compromise safety subject positive urine drug screen positive breath alcohol test . If subject present positive breath alcohol test , subject may reschedule discretion investigator designee female subject currently pregnant lactate plan become pregnant within 60 day last study drug administration history allergy hypersensitivity mastic relate drug ( e.g. , mastic gum , mastic resin , Chios mastic powder , retsina wine , Mastic Gum 500 , Mastic Gum Elma 50 , Nutricology Mastic Gum ) history allergy hypersensitivity cottonseed oil positive Hepatitis B , Hepatitis C , HIV current pending legal charge currently probation treatment investigational drug within 30 day prior first drug administration treatment phase subject , opinion investigator designee , consider suitable unlikely comply study protocol reason For PART C ( subject Alzheimer 's Disease ) males female age ≥ 55 year age Screening visit diagnosis AD , consistent criterion National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) Criteria Probable AD Diagnostic Statistical Manual Mental Disorders IV TR ( DSMIV TR ) Criteria Dementia Alzheimer 's Type MiniMental Status Evaluation ( MMSE ) score 515 , inclusive , Screening visit RosenModified Hachninski Ischemia score ≤ 4 Screening visit subject caregiver must able read , write , speak language psychometric test provide acceptable visual auditory acuity subject must reliable informant ( caregiver ) provide collateral history facilitate subject 's full participation study subject caregiver must provide write informed consent willing comply schedule visit , treatment plan , laboratory test , trial procedure subject may continue background cholinesterase inhibitor and/or memantine subject must satisfactory good health , opinion investigator , base medical history , physical examination , vital sign , 12lead ECG , laboratory test magnetic resonance imaging ( MRI ) compute tomography ( CT ) within 12 month Screening visit consistent diagnosis Probable AD without clinically significant finding diagnosis history dementia neurodegenerative disorder cause cognitive impairment ( e.g. , Parkinson 's disease , Lewy body disease , Frontotemporal Dementia , alcohol drug abuse , Traumatic Brain Injury ) . subject receive immunosuppressant , tricyclic antidepressant , anticoagulant , chemotherapeutic agent hypertension adequately control , per investigator 's judgment poorly control Type 1 and/or Type 2 diabetes , per investigator 's judgment woman child bear potential use effective method birth control medical condition psychiatric condition laboratory abnormality may increase risk associate study participation may interfere interpretation study result , , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Alzheimer ,</keyword>
	<keyword>dementia</keyword>
</DOC>